Post-Infectious IBS: When the Infection Is Gone But the Gut Won't Recover

You had a food poisoning episode overseas — perhaps in Bali, Vietnam, or India. Or a bout of Giardia picked up from a contaminated water source on a camping trip. Or perhaps it was Dientamoeba fragilis, the gut parasite that took months to diagnose and weeks to treat with targeted antibiotic therapy. Whatever the cause, your doctor confirmed the infection has cleared. The pathology results are negative. The parasites are gone. And yet, weeks or months later, you are still bloated, still cramping, still running to the bathroom with urgency, still unable to eat a normal meal without consequence. Your gut, for reasons that seem stubbornly unclear, has not returned to what it once was.

This is post-infectious irritable bowel syndrome — PI-IBS — and it is one of the most underrecognised conditions in gastroenterology. Depending on the type of infection and the individual patient, somewhere between 5 and 32 percent of people who suffer an acute gastrointestinal infection will go on to develop persistent IBS-type symptoms. For those who develop it, the impact on daily life can be profound, and the frustration of being told everything looks normal when you feel anything but is one of the most common reasons patients seek a specialist gastroenterology opinion.

What Exactly Is Post-Infectious IBS?

PI-IBS is a subset of irritable bowel syndrome that develops in the weeks to months following a clearly identifiable acute gastrointestinal infection — bacterial gastroenteritis, a parasitic illness, or viral gastro. Unlike conventional IBS, where the trigger is often unclear or multifactorial, PI-IBS has a defined starting point: patients can typically pinpoint the exact illness that preceded their gut symptoms. The condition is characterised by the same symptom cluster as IBS — abdominal pain, altered bowel habits (diarrhoea, constipation, or both), bloating, excess wind, and unpredictable urgency — but what distinguishes it from an unresolved infection is that repeat pathology testing returns negative. The bug is confirmed to be gone, yet the symptoms persist.

Which Infections Are Most Likely to Trigger It?

Almost any gastrointestinal infection can potentially trigger PI-IBS, but the risk varies significantly depending on the pathogen. Bacterial infections carry the highest documented risk: Campylobacter jejuni, Salmonella species, and certain strains of Escherichia coli are the organisms most commonly implicated in population-level studies. In one landmark prospective cohort, approximately 10 to 12 percent of patients with confirmed bacterial gastroenteritis went on to develop IBS symptoms within twelve months of their acute illness.

Parasitic infections also carry substantial risk. Giardia duodenalis is particularly well studied: post-Giardia IBS is documented across multiple populations and is thought to affect roughly 40 to 50 percent of those who experience symptomatic Giardia infection. Cryptosporidium is another recognised trigger. In clinical practice, patients with Dientamoeba fragilis and Blastocystis hominis — both of which can remain undetected for months before diagnosis — frequently report ongoing IBS-type symptoms even after successful eradication therapy, highlighting the importance of accurate testing, appropriate treatment, and thorough follow-up assessment. Viral gastroenteritis, including norovirus and rotavirus, can also precede PI-IBS, though the evidence base here is somewhat less robust.

Why Doesn't the Gut Just Heal?

This is the question patients most often ask, and the honest answer is that an acute gastrointestinal infection does far more than cause a few days of vomiting and diarrhoea. In susceptible individuals, it can produce lasting changes to the gut's immune system, nervous system, and microbial ecosystem — changes that persist long after the pathogen itself has been cleared.

An acute gut infection doesn't simply resolve and leave the gut unchanged. It can alter the gut's immune landscape, sensitise its nerve endings, and disrupt the microbial community for months or even years — even in people who appear to make a full recovery.

One key mechanism is disruption to the intestinal barrier. Acute infections damage the tight junctions between the cells lining the gut, increasing intestinal permeability and allowing luminal contents to interact with the immune cells beneath the mucosal surface. This triggers an immune response that, in some individuals, does not fully switch off. Studies of PI-IBS patients have found persistently elevated numbers of mast cells, T lymphocytes, and enterochromaffin cells in the gut mucosa — evidence of ongoing immune activation that sensitises gut nerve endings and alters motility patterns.

The microbiome is a particularly critical piece of the puzzle. The community of roughly 38 trillion microorganisms living in the gut plays a central role in regulating immune function, maintaining mucosal integrity, and modulating the enteric nervous system. An acute infection — especially one treated with broad-spectrum antibiotics — can dramatically reduce microbial diversity and deplete keystone species such as Faecalibacterium prausnitzii, whose anti-inflammatory properties are well established. In some individuals, this dysbiosis does not resolve spontaneously, and the altered microbial landscape perpetuates the very symptoms the original infection triggered.

Post-infectious changes to gut motility can also create conditions that favour the development of Small Intestinal Bacterial Overgrowth (SIBO), in which bacteria from the colon migrate into the small intestine and ferment dietary carbohydrates, producing gas, bloating, and altered bowel habits. Visceral hypersensitivity — an increased sensitivity of the gut's nerve endings to normal stimuli — is another well-documented feature of PI-IBS, explaining why patients often experience pain and discomfort at levels of gut distension that would not trouble someone with a healthy, unperturbed gut.

How Is Post-Infectious IBS Diagnosed?

There is no single test for PI-IBS. Diagnosis relies on clinical history — specifically, the temporal relationship between an acute infection and the onset of chronic symptoms — combined with thorough investigation to exclude other causes. The most important first step is confirming that the original infection has genuinely resolved, which requires appropriate pathology: stool cultures, ova and parasite microscopy (ideally with PCR-based testing), and in some cases, specific testing for organisms such as Giardia and Cryptosporidium that standard panels may not detect reliably.

Once ongoing infection has been excluded, further investigation helps characterise the underlying mechanisms. Key tests include:

• Lactulose and hydrogen breath testing for SIBO, which is significantly more prevalent in PI-IBS than in the general population. A non-invasive two-to-three-hour test, it measures hydrogen and methane gas production after ingestion of a fermentable substrate, identifying bacterial overgrowth that may be driving ongoing bloating, cramping, and altered bowel habits.

• Faecal calprotectin, a biomarker of intestinal inflammation, which helps distinguish PI-IBS (typically normal or mildly elevated) from ongoing inflammatory bowel disease or unresolved infection requiring further endoscopic evaluation.

• Coeliac serology, since acute gastrointestinal infections can occasionally unmask underlying coeliac disease in genetically susceptible individuals who were previously asymptomatic.

For patients with more complex presentations — those who have not responded to standard treatments, or those with significant ongoing symptom burden — gut microbiome sequencing provides valuable additional information. Understanding the composition of the microbiome, its diversity, and the presence or absence of keystone species can guide decisions about personalised treatment, including whether Faecal Microbiota Transplantation is appropriate.

Treatment: Targeting the Root Cause

Treatment of PI-IBS should be directed at the underlying mechanism, not just symptom suppression. When SIBO is identified on breath testing, targeted therapy with rifaximin — a non-absorbed antibiotic that acts locally within the small intestine — can produce significant and durable relief. Dietary strategies, particularly the low-FODMAP approach, reduce the fermentable carbohydrate substrate available to overgrown bacteria and can meaningfully ease bloating and urgency while longer-term gut rehabilitation proceeds.

For patients in whom significant microbiome disruption underlies their PI-IBS, Faecal Microbiota Transplantation is an emerging treatment with genuine clinical promise. Multiple randomised controlled trials have now demonstrated that FMT produces meaningful symptom improvement in IBS compared to placebo, with response rates of approximately 65 percent in well-selected patients. The rationale is straightforward: by introducing a healthy, diverse microbiome from a rigorously screened donor, FMT aims to restore the microbial ecosystem that the original infection disrupted.

At Mater Private, FMT for chronic IBS is delivered via a structured three-month program. Donors are comprehensively screened for BMI, lifestyle factors, and bacterial, parasitic, and viral panels — and crucially, for microbiome diversity, since not all donor microbiomes are equally therapeutic. Delivery methods — fresh enema, capsule-based FMT, or transcolonic infusion — are selected based on each patient's clinical profile and individual circumstances.

Gut-directed psychological therapies, including gut-directed hypnotherapy and cognitive behavioural therapy, can also contribute meaningfully to symptom management by addressing the visceral hypersensitivity and central sensitisation that accompany PI-IBS. For some patients, these approaches produce lasting improvement, particularly when combined with targeted physiological treatments addressing the underlying gut mechanisms.

You Are Not Imagining It

Post-infectious IBS is a real, biologically grounded condition. The fact that standard pathology has returned to normal does not mean your gut has recovered — it means the infection has cleared, which is an important but entirely different thing. What may remain is a gut that has been functionally altered: its barrier compromised, its immune system chronically primed, its microbiome disrupted, its nerve endings sensitised. All of these changes are identifiable with the right investigations, and all of them are treatable.

If your gut has never quite returned to normal after a bowel infection — whether it was a travel illness, a food poisoning episode, or a protracted parasitic infection — please do not accept ongoing symptoms as your new normal. A consultation with a specialist gastroenterologist can identify which mechanisms are at play and establish a treatment plan tailored specifically to your situation. Early, targeted intervention produces better outcomes than waiting and hoping the symptoms will eventually resolve on their own. You deserve a gut that works the way it should.